Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment
Citation
Yu, J.-W., Sun, L.-J., Zhao, Y.-H., Kang, P., & Yan, B.-Z. (2011). Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment. International Journal of Infectious Diseases, 15, e740–e746. doi: 10.1016/j.ijid.2011.05.018
Keywords
- Chronic hepatitis C (CHC)
- Peginterferon alpha-2a
- Ribavirin
- Treatment response
- Virologic response rates
- Sustained virologic response (SVR)
- Genotype 1
- Retrospective cohort study
- Matched study
- Rapid virologic response (RVR)
- Early virologic response (EVR) (complete and partial)
- End-of-treatment virologic response (ETVR)
- Relapse rate
- Fibrosis
- Estrogen
- Menopause
- Hormone replacement therapy (HRT)
- Anemia
- Ribavirin dose reduction
Brief
This study investigated the impact of sex on virologic response rates to peginterferon alpha-2a and ribavirin treatment in genotype 1 chronic hepatitis C patients, finding that females had higher sustained virologic response (SVR) rates when younger (<40 years), similar rates in middle age (40-50 years), and lower rates when older (51-60 years) compared to males.
Summary
This study found that the effectiveness of peginterferon alpha-2a and ribavirin treatment for genotype 1 chronic hepatitis C is influenced by sex and age. Specifically, younger women (<40 years) had higher sustained virologic response (SVR) rates, middle-aged women (40-50 years) had similar SVR rates to men, and older women (51-60 years) had lower SVR rates than men, possibly due to factors like lower ribavirin dose tolerance and lower estrogen levels. The study concludes that sex, along with age and ribavirin dosage, are independent factors affecting treatment success.
Origin: https://sci.bban.top/pdf/10.1016/j.sna.2020.112500.pdf#